Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk
NLA Recommendation on Use of Icosapent Ethyl for ASCVD Risk Reduction
For patients 45 years of age or older with clinical ASCVD, or 50 years of age or older with diabetes mellitus requiring medication and ≥1 additional risk factor,* with fasting TG 135-499 mg/dL on high-intensity or maximally tolerated statin, with or without ezetimibe, treatment with icosapent ethyl is recommended for ASCVD risk reduction.
(I, B-R)* Additional risk factors include the following, based on the entry criteria in REDUCE-IT: age (men ≥55, women ≥65 years of age), cigarette smoker or stopped smoking within 3 months, hypertension (treated or untreated), HDL-C ≤40 mg/dL for men or ≤50 mg/dL for women, hs-CRP >3.0 mg/L, renal dysfunction with creatinine clearance >30 and <60 mL/min, retinopathy, micro- or macroalbuminuria, ankle-brachial index <0.9 without symptoms of intermittent claudicatio .
Recommendation Grading
Overview
Title
Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk
Authoring Organization
National Lipid Association
Publication Month/Year
November 1, 2019
Last Updated Month/Year
January 31, 2024
Supplemental Implementation Tools
Document Type
Consensus
External Publication Status
Published
Country of Publication
US
Document Objectives
It recommends to use icosapent ethyl in selected high TG ASCVD and/or diabetic patients on statin
Target Patient Population
Patients with high TG and and ASCVD risk
Inclusion Criteria
Female, Male, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Prevention, Management
Diseases/Conditions (MeSH)
D050171 - Dyslipidemias, D015525 - Fatty Acids, Omega-3, D015118 - Eicosapentaenoic Acid, D014280 - Triglycerides
Keywords
dyslipidemia, eicosapentaenoic acid (EPA)